
About WAFT Pharma
WAFT Pharma is a Healthcare company based in Rajahmundry (India) founded in 2017. It develops and manufactures a range of pharmaceutical products, including tablets, capsules, syrups, liquids, ointments, and injections. It operates on a B2B model. Its Indian entity Waft Pharma Private Limited reported revenue of βΉ30.4 Lakh. Its focus areas include Pharmaceuticals, Drug Manufacturing and Formulations and Dosage Forms. Similar companies include Akums, Jubilant Life Sciences and Nectar Lifesciences; 2 of its 3 listed similar companies have raised funding.
Company details
WAFT Pharma, established in 2017, excels in providing healthcare solutions, producing pharmaceutical products, drug manufacturing, and formulations and dosage forms. Develops and manufactures a range of pharmaceutical products, including tablets, capsules, syrups, liquids, ointments, and injections. Committed to advancing standards, it focuses on innovation, efficiency, and delivering value to clients worldwide.
- Headquarters Rajahmundry, India
- SectorsHealthcare
- Website waftpharma.com
- Legal Name Waft Pharma Private Limited
- Date of Incorporation 26 Oct, 2017
- Jurisdiction Rajamahendravaram, Andhra Pradesh, India
- Annual Revenue₹30.4 Lakh
FY 2022 · +4519% YoY
- Net Loss-₹3.2 Lakh
FY 2022 · -10% margin
- EBITDA-₹3.1 Lakh
FY 2022 · -10% margin
Associated legal entities of WAFT Pharma
WAFT Pharma operates through Waft Pharma Private Limited (active). Its filings, financials, charges and directors are on the company page.
| Legal entity | Status | Incorporated | Registered in | Revenue (FY 2022) | Employees | Directors | Company page |
|---|---|---|---|---|---|---|---|
| Waft Pharma Private Limited CIN U33100AP2017PTC106922 | Active | 26 Oct 2017 | Rajamahendravaram, Andhra Pradesh | ₹0.3 Cr | 5 | View details |
Board of directors of Waft Pharma Private Limited (WAFT Pharma)
Waft Pharma Private Limited is the primary company behind WAFT Pharma. The board of Waft Pharma Private Limited currently have 5 directors; the longest-serving is Surya Chandra Sekhara Rao Samsani, appointed in 2017. 2 earlier directors have ceased.
| Director | Designation | Appointed | Tenure | Entity |
|---|---|---|---|---|
| Surya Chandra Sekhara Rao Samsani DIN 07966427 | Director | 26 Oct 2017 | 9 yrs | Waft Pharma Private Limited |
| Sai Dileep Viswanadha DIN 07710260 | Director | 26 Oct 2017 | 9 yrs | Waft Pharma Private Limited |
| Santhi Sree Tumati DIN 07966446 | Director | 26 Oct 2017 | 9 yrs | Waft Pharma Private Limited |
| Venkata Ramaiah Tumati DIN 08088935 | Director | 31 Mar 2018 | 8 yrs 7 mo | Waft Pharma Private Limited |
| Venkata Subbarao Gidugu DIN 08931031 | Director | 21 Oct 2020 | 6 yrs | Waft Pharma Private Limited |
Financials of WAFT Pharma
Figures of Waft Pharma Private Limited, the primary company behind WAFT Pharma, for FY 2022. Revenue was ₹30.4 Lakh (+4519% year on year). Net loss was -₹3.2 Lakh (-10% margin). EBITDA was -₹3.1 Lakh (-10% margin). Revenue has grown at a compounded annual rate of +26% over three years.
- ₹30.4 LakhRevenue · FY 2022 · +4519% YoY
- -₹3.2 LakhNet loss · -10% margin
- -₹3.1 LakhEBITDA · -10% margin
- ₹20 LakhPaid-up capital
- +26%Revenue CAGR, 3 years
Balance sheet, profit and loss, cash flow and ratios of Waft Pharma Private Limited are on its company page.
Detailed financial statements for WAFT Pharma
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Similar companies to WAFT Pharma
WAFT Pharma has 3 listed similar companies in our database, 2 of them funded. They include Akums, Jubilant Life Sciences and Nectar Lifesciences.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| akums.in | 2004 | Delhi, India | $70M | 395 | CDMO focusing on spectrum of dosage forms and therapeutic segments | |
| jubl.com | 1978 | Noida, India | Company offering a suite of R&D and manufacturing services for small molecules and generics | |||
| neclife.com | 1995 | Chandigarh, India | $46.85M | 175 | Cephalosporin APIs and generic formulations are manufactured. |
Detailed similar companies of WAFT Pharma
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track β from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about WAFT Pharma
WAFT Pharma was founded in 2017.
WAFT Pharma is headquartered in Rajahmundry, India. It is registered at Rajahmundry, Andhra Pradesh, India.
The primary company behind WAFT Pharma, Waft Pharma Private Limited, reported revenue of βΉ30.4 Lakh for FY 2022, up 4519% year on year.
WAFT Pharma, established in 2017, excels in providing healthcare solutions, producing pharmaceutical products, drug manufacturing, and formulations and dosage forms. Develops and manufactures a range of pharmaceutical products, including tablets, capsules, syrups, liquids, ointments, and injections. Committed to advancing standards, it focuses on innovation, efficiency, and delivering value to clients worldwide.
WAFT Pharma's top competitors include Jubilant Life Sciences, Akums and Nectar Lifesciences.
WAFT Pharma operates through Waft Pharma Private Limited.
The legal entities of WAFT Pharma currently have 5 directors, including Venkata Subbarao Gidugu, Venkata Ramaiah Tumati, Surya Chandra Sekhara Rao Samsani and others.